NASDAQ: UTHR

United Therapeutics (UTHR) Stock Analysis & Forecast

Nov 13 close

$591.17−2.14 (−0.4%)

Gekko Brief

AI summaryNov 9 close

United Therapeutics saw record third-quarter 2026 revenue of $833 million, with Tyvaso sales reaching $504 million, though the company pushed back a planned regulatory submission for its soft mist inhaler to 2027. Q3 EPS of $5.71 came in below the $6.01 estimate, and the stock reacted with a -5.9% move around the report. H.C. Wainwright resumed coverage with a Buy rating and a $660.00 price target, while reports also noted operating margins and GAAP profit declined even as revenue topped expectations. Separate filings detailed multiple sales by family trusts linked to Chairperson and CEO Martine A. Rothblatt under a pre-arranged Rule 10b5-1 plan.

UTHR closed at $582.46, up 3.6%, sitting above both its 50-day average of $535.33 and 200-day average of $535.04, with the shorter average above the longer one. The GekkoIndex reads 52.8, placing the stock in the Neutral zone. Gekko Fair Value stands at $676.36, leaving the price 13.9% below that level.

The next earnings date falls on 24 February 2027, 101 days away, outside a typical 20-trading-day holding window. Over the last 30 days, 2 unusual options signals have appeared, with call premium of $4.9 million against put premium of $280,000. Analyst consensus across 14 firms includes 11 buy, 2 hold and 1 sell ratings, with a consensus target of $670.93. Seasonally, the next 20 trading days have averaged a 0.6% gain over 5 years, rising in 3 of them.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

United Therapeutics price vs fair value

$665.56$591.17Nov ’25May ’26Nov ’26
Close $591.17200-day averageGekko Fair Value $665.56

United Therapeutics quick facts

Market cap
$25.18B
P/E ratio
22.4
Forward P/E
18.9
EPS, TTM
$26.49
Revenue, TTM
$3.19B
Profit margin
38.6%
Dividend yield
—
Beta
0.48
Volume
446,819 avg 500,944
1-year return
+28.1%
Typical daily move
±3%
Typical 20-day move
±5.3%
50-day average
$542.60
200-day average
$537.46
Next earnings
Feb 24 before open
Shares outstanding
42.59M
52-week range
$455.63$614.23

United Therapeutics swing-trade checklist

United Therapeutics scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

5 supportive1 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $591.17 is above the 50-day ($542.60) and 200-day ($537.46) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    51, Neutral

    Reading 51 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    11.2% below

    Price is 11.2% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 101 days

    Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +2.6% on average

    From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

United Therapeutics stock chart and price history

United Therapeutics closed at $591.17 on Nov 13, 2026, +28.1% over the past year, inside a 52-week range of $455.63 to $614.23.

Close50-day average200-day averageVolume
United Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$350$400$450$500$550DecJan 2026FebMarAprMayJunJulAugSepOctNov591.17

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+9.2%
3 months
+16.3%
6 months
+4.0%
1 year
+28.1%
The full UTHR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open UTHR in Gekko

Follow United Therapeutics through every session

Put UTHR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track UTHR in GekkoFree for 7 days. No credit card required.

About United Therapeutics

United Therapeutics is a biotechnology company focused on treatments for people with chronic and severe illnesses, some of them life-threatening. It is best known for a group of therapies used in pulmonary arterial hypertension, including Remodulin, Tyvaso, Orenitram and Adcirca, which work to ease symptoms and improve patients' ability to exercise, along with Unituxin, an antibody-based treatment for high-risk neuroblastoma.

Beyond its marketed products, the company runs a pipeline of experimental treatments and devices, among them Tyvaso DPI, the Remunity Pump, RemoPro, Ralinepag and a gene therapy called Aurora-GT aimed at lung blood vessel regeneration, and it is running trials looking at Tyvaso in patients with a form of pulmonary hypertension tied to COPD. It also works with partners such as DEKA Research & Development, MannKind and Arena Pharmaceuticals on delivery devices and drug development, and its business reaches patients in both the United States and other countries.

United Therapeutics was founded in 1996 and is headquartered in Silver Spring, Maryland. Its shares are listed on the NASDAQ under the ticker UTHR.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
unither.com

United Therapeutics GekkoIndex: the smart money zone

United Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51, in the Neutral zone, down 3.4 points over five sessions.

010051Neutral

Down 3.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying11+3.0%+3.0%+4.7%−0.3%
Accumulation199+0.9%+1.5%+1.9%+5.0%
Neutral (current zone)448+0.9%+1.8%+4.0%+9.1%
Distribution42−1.2%+0.8%+1.8%+9.4%
Selling2Too few readings yet

Average UTHR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the UTHR price, zone by zone.Track UTHR in Gekko

Is United Therapeutics stock overvalued? Gekko Fair Value

United Therapeutics trades 11.2% below Gekko Fair Value of $665.56, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what United Therapeutics shares are worth, recalculated every trading day.

$665.56

Gekko Fair Value, Nov 14, 2026

11.2% Undervalued

At the end of Aug 2026 the price was 24.6% below the estimate.

Gekko Fair ValueShare price, month end
$666$591Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open UTHR in Gekko

United Therapeutics insider and Congress trading

No open-market insider purchases were filed for United Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for UTHR in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every UTHR insider filing, plotted on the chart in Gekko.Open UTHR in Gekko

Congress trades last 90 days

No trades in UTHR were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for UTHR, plotted on the chart in Gekko.Open UTHR in Gekko

Buybacks

United Therapeutics has been buying back its own shares.

Latest authorization
$2.00B, Oct 22, 2026
Bought back, quarter ended Sep 30, 2026
$500.0M
As a share of market cap
1.99%

From company filings.

Unusual options activity last 30 days

2signals, 95% of the flagged premium in calls.

Latest: Bullish flow on Nov 4, $829K in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds UTHR.

0added0opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

United Therapeutics earnings: next date and track record

United Therapeutics reports on Feb 24, 2027, before the open (101 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±5.5%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−9.5%Feb ’25−2.3%Apr ’25−7.7%Jul ’25+9.2%Oct ’25+6.4%Feb ’26−0.5%May ’26+2.7%Aug ’26−5.9%Nov ’26

Last earnings call, Nov 4, 2026 AI summary

What they said
United Therapeutics reported Q3 2026 results highlighting execution across its cardiopulmonary and respiratory portfolio. The company has 14 programs in development targeting pulmonary hypertension, IPF, PPF, and PH-COPD, addressing approximately 1 million U.S. patients. Management emphasized its 'approve then improve' strategy, extensive IP protections extending into the 2040s, and parallel advancement of manufactured organ alternatives as a second growth pillar.
Guidance
Management expects multiple waves of innovation across nebulized, dry powder, soft mist inhaler, once-daily, and combination product platforms over the next several years. No specific revenue or earnings targets were provided in this excerpt.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026$5.71
est $6.01
−5.0%$832.5M
est $781.1M
+6.6%−5.9%
Aug 5, 2026$7.27
est $6.82
+6.6%$783.3M
est $804.6M
−2.7%+2.7%
May 6, 2026$5.82
est $6.86
−15.2%$781.5M
est $797.4M
−2.0%−0.5%
Feb 25, 2026$7.70
est $7.13
+8.0%$790.2M
est $813.1M
−2.8%+6.4%
Oct 29, 2025$7.16
est $6.89
+3.9%$799.5M
est $814.8M
−1.9%+9.2%
Jul 30, 2025$6.41
est $6.94
−7.6%$798.6M
est $801.9M
−0.4%−7.7%
Apr 30, 2025$6.63
est $6.28
+5.6%$794.4M
est $778.7M
+2.0%−2.3%
Feb 26, 2025$6.19
est $6.27
−1.2%$735.9M
est $734.7M
+0.2%−9.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

United Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for United Therapeutics is $687.14, +16.2% from the last close, from 14 firms rating the stock in the last 90 days.

$687.14consensus 12-month target, +16.2% from the last close
Low $368High $850
Buy11
Hold2
Sell1

Each firm’s latest rating in the last 90 days: 14 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9H.C. WainwrightBuy, initiated$660+11.6%
Nov 5TD CowenBuy, reiterated$700+18.4%
Nov 5Leerink PartnersBuy, reiterated$725+22.6%
Nov 5Wells FargoBuy, reiterated$703+18.9%
Nov 5Morgan StanleyHold, reiterated$568−3.9%
+4.0%average 20-day move after past Neutral readings
+2.6%average move over the next 20 trading days in the last 5 years
±3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

United Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, United Therapeutics averaged +2.6% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−5.4%2021+8.6%2022+12.5%2023−6.3%2024+7.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.0%3 of 5
Next 10 trading days−0.4%3 of 5
Next 15 trading days+0.6%3 of 5
Next 20 trading days+2.6%3 of 5
Next 30 trading days+0.9%3 of 5

For scale, UTHR’s typical 20-trading-day move in either direction is about 5.3%.

United Therapeutics market cap and key statistics

United Therapeutics’s market cap is $25.18B, with a P/E ratio of 22.4 and revenue of $3.19B over the last twelve months.

Valuation

Market cap
$25.18B
P/E ratio
22.4
Forward P/E
18.9
EPS, TTM
$26.49
Gekko Fair Value
$665.56

Trading

Volume
446,819
Avg volume, 20 days
500,944
52-week high
$614.23
52-week low
$455.63
Shares outstanding
42.59M

Financials

Revenue, TTM
$3.19B
Profit margin
38.6%
Return on equity
19.1%
Quarterly earnings growth, YoY
−20.3%

Risk and income

Beta
0.48
Typical daily move
±3%
Typical 20-day move
±5.3%

United Therapeutics peers

United Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
NBIXNeurocrine Biosciences−1.5%Neutral28.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

United Therapeutics stock FAQ

What is United Therapeutics’s market cap?

United Therapeutics’s market cap is $25.18B at the Nov 13, 2026 close of $591.17, with 42.59M shares outstanding. The shares trade on a P/E ratio of 22.4.

What is the United Therapeutics stock forecast?

The consensus analyst 12-month price target for United Therapeutics is $687.14, +16.2% from the last close. Of the 14 firms that rated the stock in the last 90 days, 11 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is United Therapeutics stock overvalued or undervalued?

On Gekko’s estimate United Therapeutics is undervalued: the Nov 13, 2026 close of $591.17 is 11.2% below Gekko Fair Value of $665.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does United Therapeutics report earnings next?

United Therapeutics is expected to report on Feb 24, 2027, before the market opens (101 days away). Analysts expect earnings of $4.95 per share on revenue of $861.6M. United Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 5.5% on average across the report.

What is United Therapeutics’s 52-week high and low?

United Therapeutics’s 52-week high is $614.23 and its 52-week low is $455.63; it closed at $591.17 on Nov 13, 2026, +28.1% over the past year.

Is United Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in United Therapeutics?

Gekko flagged 2 unusual options signals in United Therapeutics over the last 30 days, with $4.90M of flagged premium in calls and $280K in puts. The latest, bullish flow, was on Nov 4, 2026 with $829K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See United Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.